Everything above comes from Electra Therapeutics, Inc.’s own filings with the SEC, as reported. No estimates, no analyst figures, nothing adjusted.

Not reported by this filer: Total Revenue, Cost of Revenue, Gross Profit, SG&A Expense, Profit Before Tax, Income Tax Expense, Interest Income, Net Interest Income, Non-interest Income, Non-interest Expense, Provision for Credit Losses, Deposits, Loans, Inventory, Receivables, Long-term Debt (current), Short-term Borrowings, Borrowings (total), Operating Lease (total), Finance Lease (current), Finance Lease Liabilities (total), Finance Lease (noncurrent), Operating Cash Flow, Capital Expenditures, Investing Cash Flow, Financing Cash Flow, Dividends paid, Impairments, Depreciation & Amortization, Depreciation, Amortization of Intangibles, Share Repurchases, Change in Inventories, Change in Receivables, Change in Payables, Change in Payables and Accruals, Change in Customer Advances, Change in Other Operating Capital, Change in Working Capital, Acquisitions, and Shares Issued for Cash. Companies choose which XBRL tags to use, and anything untagged cannot be recovered — so these are blank rather than guessed.